Access Denied? The Unintended Consequences of Pending Drug Pricing Rules
The government of Canada now plans to bring into force new federal drug pricing regulations on 1 July 2022. We do not take issue with the goal of medication affordability, which is vital in healthcare the world over. Our concern is that the new guidelines are being implemented without due considerat...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/4/204 |
| _version_ | 1797436213945171968 |
|---|---|
| author | Alan Kaplan David J. Stewart Gerald Batist Silvana Spadafora Sandeep Sehdev Shaun G. Goodman |
| author_facet | Alan Kaplan David J. Stewart Gerald Batist Silvana Spadafora Sandeep Sehdev Shaun G. Goodman |
| author_sort | Alan Kaplan |
| collection | DOAJ |
| description | The government of Canada now plans to bring into force new federal drug pricing regulations on 1 July 2022. We do not take issue with the goal of medication affordability, which is vital in healthcare the world over. Our concern is that the new guidelines are being implemented without due consideration for three major unintended consequences: regulatory changes will lower the number of clinical trials for new medications in Canada, fewer clinical trials will mean lower research and development investments, and changes will reduce patients’ access to new medications. Access to effective medications is a cornerstone of healthcare for Canadian patients. As physicians, our duty to patient care demands that we tell the government to protect the right of Canadians to timely access to life-changing medicines. |
| first_indexed | 2024-03-09T10:58:27Z |
| format | Article |
| id | doaj.art-a9184a0365814b0a8d59816e3141c8de |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T10:58:27Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-a9184a0365814b0a8d59816e3141c8de2023-12-01T01:27:07ZengMDPI AGCurrent Oncology1198-00521718-77292022-04-012942504250810.3390/curroncol29040204Access Denied? The Unintended Consequences of Pending Drug Pricing RulesAlan Kaplan0David J. Stewart1Gerald Batist2Silvana Spadafora3Sandeep Sehdev4Shaun G. Goodman5Enhanced Care Clinic, Aurora, ON L4G 1N2, CanadaDivision of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1Y 4E9, CanadaSegal Cancer Centre, Jewish General Hospital, Montreal, QC H3T 1E2, CanadaAlgoma District Cancer Program, Sault Ste. Marie, ON P6B 0A8, CanadaDivision of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1Y 4E9, CanadaSt. Michael’s Hospital, Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, CanadaThe government of Canada now plans to bring into force new federal drug pricing regulations on 1 July 2022. We do not take issue with the goal of medication affordability, which is vital in healthcare the world over. Our concern is that the new guidelines are being implemented without due consideration for three major unintended consequences: regulatory changes will lower the number of clinical trials for new medications in Canada, fewer clinical trials will mean lower research and development investments, and changes will reduce patients’ access to new medications. Access to effective medications is a cornerstone of healthcare for Canadian patients. As physicians, our duty to patient care demands that we tell the government to protect the right of Canadians to timely access to life-changing medicines.https://www.mdpi.com/1718-7729/29/4/204oncologypharmacotherapyfundingresearchdevelopmentoutcomes |
| spellingShingle | Alan Kaplan David J. Stewart Gerald Batist Silvana Spadafora Sandeep Sehdev Shaun G. Goodman Access Denied? The Unintended Consequences of Pending Drug Pricing Rules Current Oncology oncology pharmacotherapy funding research development outcomes |
| title | Access Denied? The Unintended Consequences of Pending Drug Pricing Rules |
| title_full | Access Denied? The Unintended Consequences of Pending Drug Pricing Rules |
| title_fullStr | Access Denied? The Unintended Consequences of Pending Drug Pricing Rules |
| title_full_unstemmed | Access Denied? The Unintended Consequences of Pending Drug Pricing Rules |
| title_short | Access Denied? The Unintended Consequences of Pending Drug Pricing Rules |
| title_sort | access denied the unintended consequences of pending drug pricing rules |
| topic | oncology pharmacotherapy funding research development outcomes |
| url | https://www.mdpi.com/1718-7729/29/4/204 |
| work_keys_str_mv | AT alankaplan accessdeniedtheunintendedconsequencesofpendingdrugpricingrules AT davidjstewart accessdeniedtheunintendedconsequencesofpendingdrugpricingrules AT geraldbatist accessdeniedtheunintendedconsequencesofpendingdrugpricingrules AT silvanaspadafora accessdeniedtheunintendedconsequencesofpendingdrugpricingrules AT sandeepsehdev accessdeniedtheunintendedconsequencesofpendingdrugpricingrules AT shaunggoodman accessdeniedtheunintendedconsequencesofpendingdrugpricingrules |